Patient-Derived Xenograft (PDX) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma

Official Title

A Prospective Correlative Trial of Personalized Patient-Derived Xenograft (PDX or TumourGraft) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma

Summary:

Patients with recurrent or metastatic sarcoma will be consented to develop a patient derived xenograft (PDX or TumourGraft) model of their tumour to perform drug sensitivity testing. The purpose of the study is to evaluate the accuracy of the patient derived xenograft (PDX) model in predicting patient clinical response to the same drug treatment.

Trial Description

Primary Outcome:

  • Number of patients' whose personalized PDX model accurately predicts clinical response to therapy with same drug treatment.
Secondary Outcome:
  • Number of patients' whose personalized PDX model accurately predicts clinical response to therapy over subsequent lines of therapy.
  • Factors that impact on engraftment success.
  • Factors that impact time to drug sensitivity testing.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society